US COVID-19 State Mortality and Case Progression - A Midterm Report Card

Vernon Wen-Hau Lin; Daniel Lin; Hugh Pforsich; Xiaoming Zhang

doi:doi:10.11648/j.sjcm.20200903.14

| Peer-Reviewed

US COVID-19 State Mortality and Case Progression - A Midterm Report Card

Vernon Wen-Hau Lin, Daniel Lin, Hugh Pforsich, Xiaoming Zhang

Published in Science Journal of Clinical Medicine (Volume 9, Issue 3)

Received: 14 August 2020 Accepted: 8 September 2020 Published: 21 September 2020

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The US is leading the world in terms of the number of deaths and cases due to COVID-19. After the end of the national lockdown, there has been a significant rise in both new cases and deaths associated with COVID-19—especially in the southern and western states. This study presents an interim report of each state (50 states, DC, and Puerto Rico), in terms of mortality rate (MR, the number of cumulative deaths per 100,000 population due to COVID-19 by July 15, 2020) and Case Rate Progression (CRP, the percent change in the number of cumulative cases per 100,000 population increased from May 31 to July 15, 2020). The study provided an A - F grade report card for each state when compared to one another. The results showed that the states that received F’s in MR are the following (starting from the worst): New Jersey, New York, Massachusetts, Connecticut, Washington DC, Rhode Island, and Louisiana. The following states received F’s in CRP (starting from the worst): Arizona, Florida, South Carolina, Texas, Idaho, Arkansas, Montana, Alaska, Nevada, and Oklahoma. A poor CRP grade reflects rampant increases in new COVID-19 cases, followed by resulting increases in hospitalization, health resource utilization, and mortality. Some prior high casualty states with MR grades of F (e.g. New York, New Jersey, and Connecticut) have maintained low new case counts and received A grades in CRP. They are exemplary in terms of COVID-19 state/region-wide response and public health efforts.

Published in	Science Journal of Clinical Medicine (Volume 9, Issue 3)
DOI	10.11648/j.sjcm.20200903.14
Page(s)	58-67
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2020. Published by Science Publishing Group

Keywords

Covid-19, Mortality Rate, Case Rate Progression, Report Card

References

[1]	World Health Organization, Coronavirus disease (COVID-2019) situation report -181, World Health Organization, Geneva 2020, https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200719-covid-19-sitrep-181.pdf?sfvrsn=82352496_2, Accessed July 28, 2020.
[2]	Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382 (10): 929-936. doi: 10.1056/NEJMoa2001191.
[3]	The white house, 30 days to slow the spread, the president’s coronavirus guideline for America, https://www.whitehouse.gov/wp-content/uploads/2020/03/03.16.20_coronavirus-guidance_8.5x11_315PM.pdf#:~:text=PRACTICE GOOD HYGIENE: AVOID, Avoid touching your face, Accessed July 28, 2020.
[4]	McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N Engl J Med. 2020; 382 (21): 2005-2011. doi: 10.1056/NEJMoa2005412.
[5]	Sanchez GV, Biedron C, Fink LR, et al. Initial and Repeated Point Prevalence Surveys to Inform SARS-CoV-2 Infection Prevention in 26 Skilled Nursing Facilities — Detroit, Michigan, March–May 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 882-886. DOI: http://dx.doi.org/10.15585/mmwr.mm6927e1
[6]	Wallace M, Hagan L, Curran KG, et al. COVID-19 in Correctional and Detention Facilities — United States, February–April 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 587–590. DOI: http://dx.doi.org/10.15585/mmwr.mm6919e1
[7]	Dyal JW, Grant MP, Broadwater K, et al. COVID-19 Among Workers in Meat and Poultry Processing Facilities - 19 States, April 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (18): Published 2020 May 8. doi: 10.15585/mmwr.mm6918e3.
[8]	Moriarty LF, Plucinski MM, Marston BJ, et al. Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 347-352. DOI: http://dx.doi.org/10.15585/mmwr.mm6912e3
[9]	Payne DC, Smith-Jeffcoat SE, Nowak G, et al. SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy Service Members — USS Theodore Roosevelt, April 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 714–721. DOI: http://dx.doi.org/10.15585/mmwr.mm6923e4externalicon
[10]	Hamner L, Dubbel P, Capron I, et al. High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice — Skagit County, Washington, March 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 606–610. DOI: http://dx.doi.org/10.15585/mmwr.mm6919e6external icon.
[11]	Ghinai I, Woods S, Ritger KA, et al. Community Transmission of SARS-CoV-2 at Two Family Gatherings - Chicago, Illinois, February-March 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (15): 446-450. Published 2020 Apr 17. doi: 10.15585/mmwr.mm6915e1.
[12]	Lewis M; Sanchez R2; Auerbach S et al, COVID-19 Outbreak Among College Students After a Spring Break Trip to Mexico - Austin, Texas, March 26-April 5, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (26): 830-835. Published 2020 Jul 3. doi: 10.15585/mmwr.mm6926e1.
[13]	Centers for Disease Control and Prevention, US covid 19 graph - CDC daily new case, 2020 https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html, Accessed July 28, 2020.
[14]	Zhang X, Daniel Lin, Hugh Pforsich, and Lin VW. Physician workforce in the United States of America: forecasting nationwide shortages Human Resources for Health, 2020, 18, 8.
[15]	Zhang X, Daniel Tai, Hugh Pforsich, and Lin VW. United States Registered Nurse Workforce Report Card and Shortage Forecast: A Revisit, American Journal of Medical Quality, 2018, 33 (3), 229-236.
[16]	Juraschek SP, Zhang X, Ranganathan VK and Lin VW. US Registered Nurse Workforce Report Card and Shortage Forecast, American Journal of Medical Quality, 27 (3) 241–249, 2012.
[17]	Testing hub of Johns Hopkins University, Which U.S state meet WHO recommended testing criteria? https://coronavirus.jhu.edu/testing/testing-positivity, Accessed July 28, 2020.
[18]	Office of the Governor of Louisiana, Gov. Edwards Orders Statewide Mask Mandate, Closes Bars to On Premises Consumption as COVID-19 Continues to Spread Across Louisiana, https://gov.louisiana.gov/index.cfm/newsroom/detail/2591, Accessed July 28, 2020.
[19]	Reinhart E, Chen D. Incarceration and its disseminations: COVID-19 pandemic lessons from Chicago's Cook County Jail. Health Aff (Millwood) 2020; Epub ahead of print.
[20]	The New York Times. Coronavirus in the U.S.: Latest map and case count. New York Times. 2020.
[21]	Marcus JE, Frankel DN, Pawlak MT, et al. COVID-19 Monitoring and Response Among U.S. Air Force Basic Military Trainees — Texas, March–April 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 685–688. DOI: http://dx.doi.org/10.15585/mmwr.mm6922e2
[22]	Husch Blackwell, State-by-State Daily Updates Archive, https://www.huschblackwell.com/state-by-state-daily-updates-archive, Accessed July 28, 2020.
[23]	Wortham JM, Lee JT, Althomsons S, et al. Characteristics of Persons Who Died with COVID-19 — United States, February 12–May 18, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 923-929. DOI: http://dx.doi.org/10.15585/mmwr.mm6928e1external icon
[24]	Burke RM, Killerby ME, Newton S, et al. Symptom Profiles of a Convenience Sample of Patients with COVID-19 — United States, January–April 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 904–908. DOI: http://dx.doi.org/10.15585/mmwr.mm6928a2external icon
[25]	Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020; 15 (6): e0234765. Published 2020 Jun 23. doi: 10.1371/journal.pone.023476530.
[26]	Anne Alnor, MD, Maria B Sandberg, PhD, Charlotte Gils, MD, Pernille J Vinholt, MD, PhD, Laboratory tests and outcome for patients with COVID-19: A systematic review and meta-analysis, The Journal of Applied Laboratory Medicine,, jfaa098, https://doi.org/10.1093/jalm/jfaa098
[27]	Tahvildari A, Arbabi M, Farsi Y, Jamshidi P, et al, Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized Patients: A Systematic Review of Case Reports and Case Series, Front Med (Lausanne). 2020; 7: 231.
[28]	Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020; 383 (4): 347-358. doi: 10.1056/NEJMoa2021756.
[29]	Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 [published online ahead of print, 2020 May 6]. Ann Intern Med. 2020; M20-2003. doi: 10.7326/M20-2003.
[30]	Folegatti PM, Ewer KJ, Aley PK et al,, on behalf of the Oxford COVID Vaccine Trial Group† Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, Lancet, Published: July 20, 2020 DOI: https://doi.org/10.1016/S0140-6736(20)31604-4
[31]	Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395 (10240): 1845-1854. doi: 10.1016/S0140-6736(20)31208-3
[32]	Zhu FC, Guan XH, Li YH et al, Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebocontrolled, phase 2 trial, Lancet, July 20, 2020 https://doi.org/10.1016/ S0140-6736(20)31605-6
[33]	LA Jackson et al. ASARS-CoV-2 mRNA vaccine – preliminary report. New England Journal of Medicine. DOI: 10.1056/NEJMoa2022483 (2020).
[34]	Kellam P, Barclay W, The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection, J General Virology, 20 May 2020 https://doi.org/10.1099/jgv.0.001439
[35]	Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004; 10 (7): 676-678. doi: 10.1111/j.1469-0691.2004.00956.x.
[36]	Bhagavathula AS, Aldhaleei W, Rovetta A, and Rahmani J. Vaccines and drug therapeutics to lock down novel coronavirus disease 2019 (COVID-19): A systematic review of clinical trials. Cureus, published May 28, 2020; DOI: 10.7759/cureus.8342 (open access review article).
[37]	Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report [published online ahead of print, 2020 May 22]. N Engl J Med. 2020; NEJMoa2007764. doi: 10.1056/NEJMoa2007764.
[38]	Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk Factors of Severe Disease and Efficacy of Treatment in Patients Infected with COVID-19: A Systematic Review, Meta-Analysis and Meta-Regression Analysis [published online ahead of print, 2020 May 14]. Clin Infect Dis. 2020; ciaa576. doi: 10.1093/cid/ciaa576.
[39]	VT Chandrasekar, B Venkatesalu, HK Patel, M Spadaccini, J Manteuffel, and M Ramesh Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection, Journal of Medical Virology, (first published on July 15, 2020) https://doi.org/10.1002/jmv.26302
[40]	RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report [published online ahead of print, 2020 Jul 17]. N Engl J Med. 2020; 10.1056/NEJMoa2021436. doi: 10.1056/NEJMoa2021436.
[41]	Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020; 395 (10242): 1973-1987. doi: 10.1016/S0140-6736(20)31142-9.

Cite This Article

Plain Text BibTeX RIS

APA Style

Vernon Wen-Hau Lin, Daniel Lin, Hugh Pforsich, Xiaoming Zhang. (2020). US COVID-19 State Mortality and Case Progression - A Midterm Report Card. Science Journal of Clinical Medicine, 9(3), 58-67. https://doi.org/10.11648/j.sjcm.20200903.14

Copy | Download

ACS Style

Vernon Wen-Hau Lin; Daniel Lin; Hugh Pforsich; Xiaoming Zhang. US COVID-19 State Mortality and Case Progression - A Midterm Report Card. Sci. J. Clin. Med. 2020, 9(3), 58-67. doi: 10.11648/j.sjcm.20200903.14

Copy | Download

AMA Style

Vernon Wen-Hau Lin, Daniel Lin, Hugh Pforsich, Xiaoming Zhang. US COVID-19 State Mortality and Case Progression - A Midterm Report Card. Sci J Clin Med. 2020;9(3):58-67. doi: 10.11648/j.sjcm.20200903.14

Copy | Download

@article{10.11648/j.sjcm.20200903.14,
  author = {Vernon Wen-Hau Lin and Daniel Lin and Hugh Pforsich and Xiaoming Zhang},
  title = {US COVID-19 State Mortality and Case Progression - A Midterm Report Card},
  journal = {Science Journal of Clinical Medicine},
  volume = {9},
  number = {3},
  pages = {58-67},
  doi = {10.11648/j.sjcm.20200903.14},
  url = {https://doi.org/10.11648/j.sjcm.20200903.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjcm.20200903.14},
  abstract = {The US is leading the world in terms of the number of deaths and cases due to COVID-19. After the end of the national lockdown, there has been a significant rise in both new cases and deaths associated with COVID-19—especially in the southern and western states. This study presents an interim report of each state (50 states, DC, and Puerto Rico), in terms of mortality rate (MR, the number of cumulative deaths per 100,000 population due to COVID-19 by July 15, 2020) and Case Rate Progression (CRP, the percent change in the number of cumulative cases per 100,000 population increased from May 31 to July 15, 2020). The study provided an A - F grade report card for each state when compared to one another. The results showed that the states that received F’s in MR are the following (starting from the worst): New Jersey, New York, Massachusetts, Connecticut, Washington DC, Rhode Island, and Louisiana. The following states received F’s in CRP (starting from the worst): Arizona, Florida, South Carolina, Texas, Idaho, Arkansas, Montana, Alaska, Nevada, and Oklahoma. A poor CRP grade reflects rampant increases in new COVID-19 cases, followed by resulting increases in hospitalization, health resource utilization, and mortality. Some prior high casualty states with MR grades of F (e.g. New York, New Jersey, and Connecticut) have maintained low new case counts and received A grades in CRP. They are exemplary in terms of COVID-19 state/region-wide response and public health efforts.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - US COVID-19 State Mortality and Case Progression - A Midterm Report Card
AU  - Vernon Wen-Hau Lin
AU  - Daniel Lin
AU  - Hugh Pforsich
AU  - Xiaoming Zhang
Y1  - 2020/09/21
PY  - 2020
N1  - https://doi.org/10.11648/j.sjcm.20200903.14
DO  - 10.11648/j.sjcm.20200903.14
T2  - Science Journal of Clinical Medicine
JF  - Science Journal of Clinical Medicine
JO  - Science Journal of Clinical Medicine
SP  - 58
EP  - 67
PB  - Science Publishing Group
SN  - 2327-2732
UR  - https://doi.org/10.11648/j.sjcm.20200903.14
AB  - The US is leading the world in terms of the number of deaths and cases due to COVID-19. After the end of the national lockdown, there has been a significant rise in both new cases and deaths associated with COVID-19—especially in the southern and western states. This study presents an interim report of each state (50 states, DC, and Puerto Rico), in terms of mortality rate (MR, the number of cumulative deaths per 100,000 population due to COVID-19 by July 15, 2020) and Case Rate Progression (CRP, the percent change in the number of cumulative cases per 100,000 population increased from May 31 to July 15, 2020). The study provided an A - F grade report card for each state when compared to one another. The results showed that the states that received F’s in MR are the following (starting from the worst): New Jersey, New York, Massachusetts, Connecticut, Washington DC, Rhode Island, and Louisiana. The following states received F’s in CRP (starting from the worst): Arizona, Florida, South Carolina, Texas, Idaho, Arkansas, Montana, Alaska, Nevada, and Oklahoma. A poor CRP grade reflects rampant increases in new COVID-19 cases, followed by resulting increases in hospitalization, health resource utilization, and mortality. Some prior high casualty states with MR grades of F (e.g. New York, New Jersey, and Connecticut) have maintained low new case counts and received A grades in CRP. They are exemplary in terms of COVID-19 state/region-wide response and public health efforts.
VL  - 9
IS  - 3
ER  -

Copy | Download

Author Information

Vernon Wen-Hau Lin

Physical Medicine and Rehabilitation Service, The Hershel “Woody” Williams VA Medical Center, Huntington, West Virginia, USA
Daniel Lin

Mechanical Engineering, University of California, Davis, California, USA
Hugh Pforsich

Accounting Department, California State University, Sacramento, California, USA
Xiaoming Zhang

Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Vernon Wen-Hau Lin, Daniel Lin, Hugh Pforsich, Xiaoming Zhang. (2020). US COVID-19 State Mortality and Case Progression - A Midterm Report Card. Science Journal of Clinical Medicine, 9(3), 58-67. https://doi.org/10.11648/j.sjcm.20200903.14

Copy | Download

ACS Style

Vernon Wen-Hau Lin; Daniel Lin; Hugh Pforsich; Xiaoming Zhang. US COVID-19 State Mortality and Case Progression - A Midterm Report Card. Sci. J. Clin. Med. 2020, 9(3), 58-67. doi: 10.11648/j.sjcm.20200903.14

Copy | Download

AMA Style

Vernon Wen-Hau Lin, Daniel Lin, Hugh Pforsich, Xiaoming Zhang. US COVID-19 State Mortality and Case Progression - A Midterm Report Card. Sci J Clin Med. 2020;9(3):58-67. doi: 10.11648/j.sjcm.20200903.14

Copy | Download

@article{10.11648/j.sjcm.20200903.14,
  author = {Vernon Wen-Hau Lin and Daniel Lin and Hugh Pforsich and Xiaoming Zhang},
  title = {US COVID-19 State Mortality and Case Progression - A Midterm Report Card},
  journal = {Science Journal of Clinical Medicine},
  volume = {9},
  number = {3},
  pages = {58-67},
  doi = {10.11648/j.sjcm.20200903.14},
  url = {https://doi.org/10.11648/j.sjcm.20200903.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjcm.20200903.14},
  abstract = {The US is leading the world in terms of the number of deaths and cases due to COVID-19. After the end of the national lockdown, there has been a significant rise in both new cases and deaths associated with COVID-19—especially in the southern and western states. This study presents an interim report of each state (50 states, DC, and Puerto Rico), in terms of mortality rate (MR, the number of cumulative deaths per 100,000 population due to COVID-19 by July 15, 2020) and Case Rate Progression (CRP, the percent change in the number of cumulative cases per 100,000 population increased from May 31 to July 15, 2020). The study provided an A - F grade report card for each state when compared to one another. The results showed that the states that received F’s in MR are the following (starting from the worst): New Jersey, New York, Massachusetts, Connecticut, Washington DC, Rhode Island, and Louisiana. The following states received F’s in CRP (starting from the worst): Arizona, Florida, South Carolina, Texas, Idaho, Arkansas, Montana, Alaska, Nevada, and Oklahoma. A poor CRP grade reflects rampant increases in new COVID-19 cases, followed by resulting increases in hospitalization, health resource utilization, and mortality. Some prior high casualty states with MR grades of F (e.g. New York, New Jersey, and Connecticut) have maintained low new case counts and received A grades in CRP. They are exemplary in terms of COVID-19 state/region-wide response and public health efforts.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - US COVID-19 State Mortality and Case Progression - A Midterm Report Card
AU  - Vernon Wen-Hau Lin
AU  - Daniel Lin
AU  - Hugh Pforsich
AU  - Xiaoming Zhang
Y1  - 2020/09/21
PY  - 2020
N1  - https://doi.org/10.11648/j.sjcm.20200903.14
DO  - 10.11648/j.sjcm.20200903.14
T2  - Science Journal of Clinical Medicine
JF  - Science Journal of Clinical Medicine
JO  - Science Journal of Clinical Medicine
SP  - 58
EP  - 67
PB  - Science Publishing Group
SN  - 2327-2732
UR  - https://doi.org/10.11648/j.sjcm.20200903.14
AB  - The US is leading the world in terms of the number of deaths and cases due to COVID-19. After the end of the national lockdown, there has been a significant rise in both new cases and deaths associated with COVID-19—especially in the southern and western states. This study presents an interim report of each state (50 states, DC, and Puerto Rico), in terms of mortality rate (MR, the number of cumulative deaths per 100,000 population due to COVID-19 by July 15, 2020) and Case Rate Progression (CRP, the percent change in the number of cumulative cases per 100,000 population increased from May 31 to July 15, 2020). The study provided an A - F grade report card for each state when compared to one another. The results showed that the states that received F’s in MR are the following (starting from the worst): New Jersey, New York, Massachusetts, Connecticut, Washington DC, Rhode Island, and Louisiana. The following states received F’s in CRP (starting from the worst): Arizona, Florida, South Carolina, Texas, Idaho, Arkansas, Montana, Alaska, Nevada, and Oklahoma. A poor CRP grade reflects rampant increases in new COVID-19 cases, followed by resulting increases in hospitalization, health resource utilization, and mortality. Some prior high casualty states with MR grades of F (e.g. New York, New Jersey, and Connecticut) have maintained low new case counts and received A grades in CRP. They are exemplary in terms of COVID-19 state/region-wide response and public health efforts.
VL  - 9
IS  - 3
ER  -

Copy | Download